Monday, April, 15, 2024 02:27:40

The on-demand supply service would be made available to any client of Clinigen that is running clinical trials.

Global pharmaceutical and services firm Clinigen Group plc has recently announced that the Clinical Trial Service (CTS) business of the company has extended its European clinical trial supply agreement with Accord Healthcare. Apparently, an on-demand service for Accord’s products is also being offered to pharma companies by Clinigen.

According to Clinigen, for all enquiries regarding clinical trial supply, the sole point of contact is the CTS team, which also ensures secure and effective supply chain for distributing the European product portfolio of Accord to clinical trial contract packagers, contract research organizations (CROs), pharmaceutical manufacturers as well as other specialist service providers. The drugs are distributed for use as adjunctive, rescue, co-therapy and comparator drugs in clinical trials.

Citing sources familiar with the matter, the on-demand supply service would be made available to any client of Clinigen that is running clinical trials. They would be provided with instant access to significant products from the Accord’s portfolio of generic oncology injectable products. Ready for instant dispatch to existing and new clinical trials, products would be held on consignment in large batch sizes.

Shaun Chilton, Group CEO of Clinigen, mentioned that this extended agreement is built on the strong partnership the company has with Accord to provide access to its medicines for clinical trial use. The on-demand offering launch shows Clinigen’s capability across the Group and its specialisms in the distribution and supply of medicines. Capabilities like these allow the company to provide the best possible service to clients running clinical trials.

Accord Healthcare’s Senior Vice President Commercial for EMENA region, Phill Semmens, stated that over the past six years, Accord and Clinigen have built a strong collaboration which is persistently growing with the agreement for including solid dose oral products.

Semmens further said that this partnership’s scope is a first for the industry, which would allow the company to ensure that its products are available as comparators in diverse vital clinical trials, assisting in identification of new treatment options and to further medical knowledge for improving patient care.